Spots Global Cancer Trial Database for A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
Official Title: Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation
Study ID: NCT02950064
Interventions
Study Description
Brief Summary: This is a phase 1, Open-label, multicenter Dose Escalation study of BTP-114, a novel platinum product, in patients with advanced solid tumors and BRCA or other DNA repair mutation. This clinical study is comprised of 2 sequential parts: Part 1 (Dose Escalation) and Part 2 (Expansion). The purpose of this study is to evaluate the safety, pharmacokinetics and the anti-cancer activity of BTP-114.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Placon Therapeutics Clinical Trial Site, Sarasota, Florida, United States
Placon Therapeutics Clinical Trial Site, Boston, Massachusetts, United States
Placon Therapeutics Clinical Trial Site, Boston, Massachusetts, United States
Placon Therapeutics Clinical Trial Site, Saint Louis, Missouri, United States
Placon Therapeutics Clinical Trial Site, Cleveland, Ohio, United States
Placon Therapeutics Clinical Trial Site, Oklahoma City, Oklahoma, United States
Placon Therapeutics Clinical Trial Site, Nashville, Tennessee, United States
Placon Therapeutics Clinical Trial Site, Houston, Texas, United States
Contact Details
Name: Erika P Hamilton, MD
Affiliation: Tennessee Oncology, PLLC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
